DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

DHR·Danaher Corporation

$.
+. (+.%)
After Hours
High
$199.84
Open
$197.58
Market Cap
140.88B
52W High
$242.80
Low
$195.05
P. Close
$198.95
P/E
38.19
52W Low
$160.93
Fwd P/E
21.53
DailyIQ Est.
$254.00
Technical Score (1D)
82
BUY
News Sentiment
47
MIXED
The CE Mark awarded to Beckman Coulter’s Access p‑Tau217 assay under the new IVDR framework expands the product’s potential reach across EU healthcare providers, potentially lifting diagnostics revenue in the coming weeks. This regulatory win could translate into higher earnings for Danaher, but the market has reacted cautiously, reflecting broader softness in the sector. Investors should watch how quickly the company converts the CE approval into sales growth over the next 1–10 trading days, as early revenue upticks would validate the milestone. Meanwhile, DHR trades at a lower P/E than VTRS and offers a higher dividend yield, positioning it as a value play with a conservative risk profile that may appeal to income‑focused investors. The combination of a regulatory milestone and attractive valuation could support a rebound in the stock if sales lift materializes. Key watch items include quarterly guidance on diagnostics revenue, any updates on EU market penetration, and the company’s dividend policy. Additionally, monitor broader market sentiment for defensive sectors, as DHR’s diagnostics business is less sensitive to cyclical swings. Finally, keep an eye on the next earnings release for confirmation of revenue impact and any guidance revisions.
Earnings Summary
Danaher Corporation (DHR) is a global manufacturer and marketer of products and services across biotechnology, life sciences, and diagnostics, operating through three key segments that supply instruments, consumables, and clinical solutions to professional, medical, and industrial customers. In the healthcare diagnostics and research sector, the company’s earnings are driven by recurring consumable sales and incremental product launches. In the most recent two quarters with data, Q1 2026 reported an EPS of $2.06 versus an estimate of $1.85656 and revenue of $5.951 billion, while Q4 2025 delivered an EPS of $2.23 versus an estimate of $2.1743 and revenue of $6.838 billion; the prior two quarters, Q3 2025 and Q2 2025, posted EPS of $1.89 and $1.80 and revenues of $6.053 billion and $5.936 billion, respectively. Danaher beat estimates in each of the last five quarters, with only Q4 2024 missing the EPS estimate, reflecting a consistent earnings beat pattern. Historically, the company has shown YoY revenue growth from $6.538 billion in Q4 2024 to $6.838 billion in Q4 2025, a 4.6 % increase, and EPS growth from $2.14 to $2.23, a 4.2 % rise, underscoring steady top‑line and profitability momentum. Recent news highlights the FDA 510(k) clearance of Masimo’s AI‑enabled respiratory‑depression detection feature on the Radius VSM platform, which expands Danaher’s pulse‑oximetry line into actionable, AI‑driven hospital monitoring and could increase recurring consumables revenue; HSBC’s price‑target cut to $230 from $270 also signals a reassessment of growth expectations. Investors should watch the July 21 earnings call for guidance on product adoption, the projected revenue impact of the new feature, and any updates on regulatory developments, as these factors will shape the company’s near‑term earnings trajectory.

EPS

EstBeatMiss
$1.56$1.75$1.94$2.13$2.32Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.84 - -
Q1'26$1.86$2.06+11.0%
Q4'25$2.17$2.23+2.6%
Q3'25$1.72$1.89+9.8%
Q2'25$1.64$1.80+9.5%
Q1'25$1.64$1.88+14.4%

Revenue

EstBeatMiss
$5.6B$5.9B$6.3B$6.7B$7.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.2B - -
Q1'26$6.1B$6.0B-2.9%
Q4'25$6.9B$6.8B-0.5%
Q3'25 - $6.1B -
Q2'25 - $5.9B -
Q1'25 - $5.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DHR Stock Snapshot

DHR is currently trading at $199.05, giving Danaher Corporation a market cap of 140.88B and a P/E ratio of 38.2. Today's range spans $195.05–$199.84, with shares opening at $197.58 and moving up $0.10 (0.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 47/100.

Over the past year DHR has traded between $160.93 and $242.80 - the current price is +23.7% off the 52-week low and -18.0% from the high. 34 analysts cover the stock with a Buy consensus and a mean 12-month target of $242.26 (range $200.00–$310.00), implying upside of +21.7%.

DHR is scoring 82/100 technically (BUY) and sits at $199.05 - in the middle of its 52-week range in its $160.93–$242.80 annual range. Sentiment at 47/100 is neutral. At 140.88B in Healthcare market cap The current P/E ratio stands at 38.2., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.

What makes DHR's BUY setup (82/100) particularly actionable at 140.88B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $199.05 (in the middle of its 52-week range in $160.93–$242.80), with sentiment running neutral at 47/100, the setup rewards conviction-sized positioning more than it does speculative small bets.